|19-11-21||EdiGene to Present Data on Manufacturing Scale-up and Preclinical Development of its Leading Gene Editing Therapeutic Program to Treat Patients with β-Thalassemia Major|
|19-09-17||Genome Editing Biotech EdiGene Raises $11 M in Series Pre-B2 Financing and Forms Research Collaboration to Develop Allogeneic T-cell Therapeutics for Cancer|
|19-07-17||Programmable RNA editing by recruiting endogenous ADAR using engineered RNAs|
|19-07-17||Abcam Enters Cell Editing Market Through Acquisition of EdiGene’s Knock-out Cell Lines and Lysates Portfolio|
|19-04-03||EdiGene Announced Strategic Collaboration with Genetron|
|19-02-13||Genome Editing Biotech EdiGene Raises $10 Million in Series pre-B Plus Financing and Strengthens Management Team|
|18-08-10||Genome Editing Biotech EdiGene Raises $15 Million in Series pre-B Financing|
|18-08-10||Genome Editing Biotech EdiGene Names Dong Wei, Ph.D., MBA as its Chief Executive Officer|
Life Science Park, 22 KeXue Yuan Road,Changping District, Beijing, P.R. China
EdiGene Guangzhou Inc.
Building 10, No.6, Nanjiang Second Road, Nansha District, Guangzhou, China
EDIGENE BIOTECHNOLOGY USA INC.
245 FIRST STREET, RIVERVIEW II, 18TH FLOORCAMBRIDGE, MA 02142 USA